EBMT 2023 | The benefits of CAR-T therapy in 2L over 3L in R/R DLBCL
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the clinical benefits of using CAR-T therapy in the second-line setting rather than in third-line in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Data from the ZUMA-7 (NCT03391466) trial demonstrated that second-line CAR-T therapy yields improvements in event-free survival (EFS) as well as overall survival (OS) over standard of care (SOC). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
With the data coming from these two prospective clinical trials that were looking at second line, I think that CAR-T should be used in this specific subgroup of patients in second line and not in third line. For instance, the ZUMA-7 trial has been able to demonstrate, not only benefits in front of the standard of care in terms of event-free survival, but there was a press release indicating that there were benefits also in terms of overall survival...
With the data coming from these two prospective clinical trials that were looking at second line, I think that CAR-T should be used in this specific subgroup of patients in second line and not in third line. For instance, the ZUMA-7 trial has been able to demonstrate, not only benefits in front of the standard of care in terms of event-free survival, but there was a press release indicating that there were benefits also in terms of overall survival. And this indicates that in spite of the fact that many of the patients failing the standard of care were treated with CAR T in third line, that the use of CAR T in second line failure and eventually improve the overall survival in these patients. So, in principle with the data that we have, CAR T in specific subgroups of patients should be better used in second and not in third line or plus.
Read more...
Disclosures
Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria.
